医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

India’s Refractive Surgery Society Awards Special Gold Medal to LENSAR CEO Nicholas T. Curtis

2015年07月06日 PM09:00
このエントリーをはてなブックマークに追加


 

ORLANDO, Fla. & CHENNAI, India

The Intraocular Implant and Refractive Society of India (IIRSI) awarded a Special Gold Medal to Nicholas T. Curtis, CEO of LENSAR, Inc., a global leader in next generation femtosecond laser technology for refractive cataract surgery, for his outstanding contribution to industry. The award was presented in Chennai at the IIRSI Conference by Dr. C. Vijaya Bhaskar, honorable Minister for Health, Medical Education and Family Welfare for the state of Tamilnadu, with the society’s Secretary General Dr. Amar Agarwal.

“I am incredibly honored by this recognition from the ophthalmology community of India,” said Mr. Curtis. “It is a privilege to partner with a renowned surgeon such as Dr. Agarwal in bringing innovative, best in class laser cataract technology to India. Working together, we can advance the standard of care, improve outcomes and the quality of life for cataract patients in India.”

Immediately following the award ceremony, Mr. Curtis and Dr. Agarwal introduced the suite of five new application technologies integrated into the LENSAR® Laser System with Streamline™ to the conference’s estimated 4,000 attending ophthalmologists from around the globe, as well the guest of honor Nawab Mohammed Abdul Ali Azimjah, Prince of Arcot. Dr. Agarwal, one of the world’s foremost authorities on cataract surgery, has selected the LENSAR Laser System for his Eye Hospital Network and will begin offering femtosecond laser assisted cataract surgery at its Chennai location.

“We chose LENSAR because we believe it to be the most robust and versatile femtosecond cataract technology available for cataract procedures and the mobile, small footprint of the LENSAR Laser System makes it an optimal choice for our network,” said Dr. Agarwal. “We see many mature, hard cataracts in our hospitals which greatly informed our choice of a femtosecond laser platform to launch our laser-assisted cataract practice. LENSAR’s superior fragmentation capabilities and phaco energy reduction were important benefits over other platforms. We are also impressed with LENSAR’s advanced imaging technology allowing us to better visualize the eye, which will enable a more customized procedure for better outcomes.”

The LENSAR Laser System is the only femtosecond cataract laser on the market today developed specifically for refractive cataract surgery and features quick and easy patient docking, as well as superior imaging capabilities including LENSAR’s proprietary Augmented Reality™ 3-D reconstruction. This technology facilitates enhanced procedure outcomes by allowing the physician to develop individualized treatment plans including precise laser delivery and efficient lens fragmentation that can reduce, and potentially eliminate, the amount of energy delivered into the eye. As the first femtosecond laser cataract platform to enable automation of key surgical procedure planning and execution elements, the LENSAR Laser System with Streamline include:

  • Wireless integration with Cassini
  • Iris registration
  • Astigmatism management with arcuate incision planning and steep axis corneal marking
  • Automatic cataract density imaging
  • Automatic customized fragmentation patterns

“Because of the type and number of cataract patients we see, the choice of a laser was very important. Femto cataract procedures have been available internationally and here in India for several years, but we waited for the technology to mature,” continued Dr. Agarwal. “We invested in the very best in precision, safety and versatility for our patients. With the LENSAR Laser System we are confident we have a robust instrument that can easily perform to our high standards to offer this new and innovative option in treating cataracts.”

About Dr. Agarwal’s Eye Hospital

Dr. Agarwal’s Eye Hospital operates in more than eight countries at over 50 locations, and is one of the world’s largest provider chains of high quality surgery. Dr. Amar Agarwal, M.B.B.S., M.S., F.R.C.S., F.R.C. Ophth., is the Chief Clinical Director of Doctor Agarwal’s Eye Hospital Ltd., and one of the world’s most prolific authors on the subject of cataract surgery. A professor of ophthalmology at Ramachandra Medical College in Chennai and the author of approximately 50 books on the subject, Dr. Agarwal is recognized internationally as a leading expert in cataract surgery, responsible for many innovations in technology and technique. As a result of his distinguished career, Dr. Agarwal is the recipient of some of ophthalmology’s most prestigious honors including the Barraquer and Kelman awards.

About LENSAR, Inc.

LENSAR, Inc., is a global leader in next generation femtosecond laser technology for refractive cataract surgery. The LENSAR Laser System offers cataract surgeons precision, accuracy, and efficiency while optimizing overall visual outcomes. LENSAR’s proprietary Augmented Reality™ technology — reconstructed 3-D imaging, measurement, and guidance system — offers quick and easy patient docking and provides high-resolution ocular images in a single scan. This technology facilitates enhanced procedure outcomes by allowing the physician to develop individualized treatment plans including precise laser delivery and efficient lens fragmentation that can reduce, and potentially eliminate, phaco energy. The LENSAR Laser System also offers the industry’s smallest laser footprint and thoughtful ergonomic design that accommodates most operating rooms.

With the FDA clearance and recent CE Mark of five application upgrades, offered as Streamline™, the LENSAR Laser System becomes the first to offer automation and customization of essential steps of the refractive cataract surgery procedure. The LENSAR Laser System has been cleared by the FDA for anterior capsulotomy, lens fragmentation, and corneal and arcuate incisions. For other indications it is an investigational device limited by U.S. law to investigational use only. For more information, please visit www.lensar.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150706005232/en/

CONTACT

LENSAR
Media Contact:
Liana Miller for LENSAR
liana@engagedcommunication.net
949-276-8920
or
Investor
Inquiries:

Peter J. Mariani, CFO
888-536-7271

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent